RT Journal Article
SR Electronic
T1 No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.10.20060699
DO 10.1101/2020.04.10.20060699
A1 Mahévas, Matthieu
A1 Tran, Viet-Thi
A1 Roumier, Mathilde
A1 Chabrol, Amélie
A1 Paule, Romain
A1 Guillaud, Constance
A1 Gallien, Sébastien
A1 Lepeule, Raphael
A1 Szwebel, Tali-Anne
A1 Lescure, Xavier
A1 Schlemmer, Frédéric
A1 Matignon, Marie
A1 Khellaf, Medhi
A1 Crickx, Etienne
A1 Terrier, Benjamin
A1 Morbieu, Caroline
A1 Legendre, Paul
A1 Dang, Julien
A1 Schoindre, Yoland
A1 Pawlotski, Jean-Michel
A1 Michel, Marc
A1 Perrodeau, Elodie
A1 Carlier, Nicolas
A1 Roche, Nicolas
A1 de Lastours, Victoire
A1 Mouthon, Luc
A1 Audureau, Etienne
A1 Ravaud, Philippe
A1 Godeau, Bertrand
A1 Costedoat-Chalumeau, Nathalie
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.10.20060699.abstract
AB Background Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies.Methods We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoint was transfer to intensive care unit (ICU) within 7 days from inclusion and/or death from any cause. Analyses were adjusted for confounding factors by inverse probability of treatment weighting.Results This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47–1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13–2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65–2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation.Interpretation These results do not support the use of HCQ in patients hospitalised for documented SARS-CoV-2-positive hypoxic pneumonia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was obtained for this studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from authors upon reasonable request.